The approved uses of oncology treatments are generally based on the cancer site, cancer stage, disease characteristics, and line of therapy. Concerns have been raised about the appropriateness of off-label use of drugs in oncology, particularly with novel, high-cost agents.
In a review of studies examining tobacco use among patients diagnosed with cancer, the rate of patients who were smokers at the time of their cancer diagnosis ranged from 46% to 75%. Among the patients who were smokers at diagnosis, the reviewers estimated that up to 58% of patients continued to smoke after initiating cancer therapy.
Results 1 - 10 of 44